DESMOGLEIN-4 DEFICIENCY IMPAIRS HUMORAL IMMUNITY INDUCED BY OVA INTRADERMAL ADMINISTRATION

MICHEL, MARÍA CECILIA; TRONCOSO MARIANA; MORENO-SOSA MARÍA TAMARA; NEIRA, FLAVIA JUDITH; CAMPO VERDE ARBOCCÓ FIORELLA; SOAJE, MARTA; MOISO, A; PIETROBON, ELISA OLIVIA; INOCCENTI BADANO AC; JAHN, GRACIELA A.; VALDEZ, SUSANA R.; MACKERN OBERTI, JUAN PABLO

SAN LUIS

Congreso; Sociedad de Biología de Cuyo; 2021

Sociedad de Biología de Cuyo

Desmogleins (Dsg) are transmembraneproteins located in desmosomes and play a critical role in the cell-cell adhesionof epithelial cells. Dsg-4 deficiency is associated with sharp hair loss inhumans, mice, and rats. Recently, we have reported a clear link between Dsg-4deficiency, exacerbated inflammation, and psoriasis-like lesions afterimiquimod (IMQ) administration. However, the role of Dsg-4 in humoral immunityhas not been addressed. Therefore, this work aimed to study the impact of Dsg-4 deficiencyin OVA-specific IgG induction. For this purpose, OFA hr/hrdeficient in Dsg-4, and wild-type Sprague-Dawley (SD) rats were inoculatedintradermally with PBS-OVA. IMQ, or Vaseline (Vas), was administered topicallyafter four hours from OVA injection and for the following three days. Two weeks later, serum samples were obtained to determined OVA-specific IgGlevels by ELISA. Surprisingly, OFA rats displayedlower OVA-specific IgG levels compared to SD group (OFA 0.118±0.09 vs D0.745±0.171 t test, p<0.0001). Although, IMQadministration induced a decreased OVA-specific IgG levels in both groups (SD Vas0.745±0.171 vs SDIMQ 0.446±0.236, t test, p<0.001; OFAVas 0.118±0.095 vsOFAIMQ 0.043±0.027; t test; p<0.01). These results suggest thatdesmoglein-4 promotes adaptive immunity in response to OVA challenge. Althoughthe underlying mechanism remains unknown, Dsg-4 deficiency may be impairing thefirst immune response events such as antigen draining to lymphatic nodes,antigen presentation, and germinal center reaction. Although further researchis needed, these results highlight the role of Dsg-4 in humoral immunity afterexposure to an antigen and administration of an immune modulator in the skin.@font-face{font-family:Arial;panose-1:2 11 6 4 2 2 2 2 2 4;mso-font-charset:0;mso-generic-font-family:auto;mso-font-pitch:variable;mso-font-signature:-536859905 -1073711037 9 0 511 0;}@font-face{font-family:"Cambria Math";panose-1:2 4 5 3 5 4 6 3 2 4;mso-font-charset:0;mso-generic-font-family:auto;mso-font-pitch:variable;mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face{font-family:Calibri;panose-1:2 15 5 2 2 2 4 3 2 4;mso-font-charset:0;mso-generic-font-family:auto;mso-font-pitch:variable;mso-font-signature:-536870145 1073786111 1 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal{mso-style-unhide:no;mso-style-qformat:yes;mso-style-parent:"";margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;mso-pagination:widow-orphan;font-size:11.0pt;font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:"Times New Roman";}.MsoChpDefault{mso-style-type:export-only;mso-default-props:yes;font-family:Calibri;mso-ascii-font-family:Calibri;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:minor-bidi;mso-ansi-language:ES-TRAD;}div.WordSection1{page:WordSection1;}